Kristalose is a unique, dry powder, crystalline formulation of lactulose that is designed to enhance patient compliance during treatment of acute and chronic constipation. It is the only prescription laxative available in pre-measured powder packets, making it convenient and easily portable.
Poly and Cumberland's multi-year co-promotion partnership will expand current promotional support for Kristalose across
Under the terms of the agreement, Cumberland shall provide co-promotional payments to Poly based on the incremental prescriptions generated by Poly's sales organization. Poly projects their efforts will significantly grow the sales of Kristalose during the multi-year agreement term. Cumberland will provide sales training and promotional materials for Poly's sales professionals who will focus on new physician segments in support of the brand.
"Kristalose is an outstanding product with considerable untapped potential," said Chase Williams, President of
"We welcome Poly as a co-promotional partner and believe this collaboration will provide a new growth driver for Kristalose, our largest selling product," said
Kristalose is the only branded prescription laxative product that features the established safety and efficacy of lactulose, with the convenience of a pre-measured powder dose. Kristalose dissolves quickly in 4 oz. of water, offering patients a virtually tasteless, grit-free and essentially calorie-free alternative to lactulose syrups. There are no age limitations or length of use restrictions for Kristalose and it is the only osmotic prescription laxative still sampled to physicians. For full prescribing information, including boxed warning, visit www.kristalose.com.
Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in
Cumberland is also dedicated to developing innovative products that address unmet medical needs. The Company's product candidates in clinical development include: Hepatoren® (ifetroban) Injection for the treatment of hepatorenal syndrome, Boxaban® (ifetroban) Oral Capsule for patients suffering from aspirin exacerbated respiratory disease, Vasculan™ (ifetroban) Oral Capsule for the treatment of systemic sclerosis, and Portaban™, for the treatment of portal hypertension.
For more information on
Important Note Regarding Forward Looking Statements
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur.
As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations.
These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-kristalose-growth-driver-established-through-co-promotion-agreement-300445907.html
News Provided by Acquire Media